Déjà vu for Zafgen: Still fretting about lingering cardio concerns, FDA clamps a hold on lead obesity drug -- shares plunge
Two years after Zafgen torched its lead obesity compound following an ugly crash in late-stage testing that cost lives, the FDA is still fretting whether …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
